Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$14.38-1.4%$16.46$7.75▼$19.09$1.90B1.54549,456 shs855,291 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%-7.37%-6.17%-10.76%+29.12%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTACentessa Pharmaceuticals2.9371 of 5 stars3.53.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.00Buy$27.7192.73% UpsideCurrent Analyst Ratings BreakdownLatest CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/7/2025CNTACentessa PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$27.00 ➝ $27.002/10/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy1/7/2025CNTACentessa PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M276.66N/AN/A$2.42 per share5.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$151.09M-$1.99N/AN/AN/AN/A-52.13%-38.01%5/12/2025 (Estimated)Latest CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.1521.5221.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals11.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200131.85 million116.56 millionOptionableCNTA HeadlinesRecent News About These CompaniesPiper Sandler Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Overweight RecommendationMarch 31 at 4:11 PM | msn.comB. Riley Issues Negative Estimate for CNTA EarningsMarch 31 at 1:33 AM | marketbeat.comAnalysts Offer Predictions for CNTA Q3 EarningsMarch 28 at 6:15 AM | marketbeat.comNotable Two Hundred Day Moving Average Cross - CNTAMarch 28 at 4:49 AM | nasdaq.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $163,400.00 in StockMarch 27, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - What's Next?March 27, 2025 | marketbeat.comCentessa Pharmaceuticals' (CNTA) "Buy" Rating Reaffirmed at GuggenheimMarch 27, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CNTA Q1 Earnings?March 27, 2025 | marketbeat.comGregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMarch 27, 2025 | insidertrades.comCentessa reports Q4 EPS (84c), consensus (35c)March 25, 2025 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Releases Earnings ResultsMarch 25, 2025 | marketbeat.comCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024March 24, 2025 | globenewswire.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesMarch 22, 2025 | marketbeat.comIqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMarch 20, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $120,190.00 in StockMarch 20, 2025 | marketbeat.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of StockMarch 20, 2025 | insidertrades.comPlatinum Investment Management Ltd. Sells 59,423 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)March 20, 2025 | marketbeat.comCentessa Pharmaceuticals (CNTA) to Release Earnings on ThursdayMarch 20, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Significant Growth in Short InterestMarch 17, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's What HappenedMarch 15, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Buy" by BrokeragesMarch 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$14.38 -0.21 (-1.44%) Closing price 04:00 PM EasternExtended Trading$14.38 +0.00 (+0.03%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
